Camargo Taps PhDs, Postdoctoral Researchers for Training
Camargo Pharmaceutical Services has tapped academic organizations close to its Raleigh, NC site in a unique internship program...
Camargo Pharmaceutical Services, which specializes in 505(b)(2) approval pathway drug development, has tapped academic organizations close to its Raleigh, NC site in a unique internship program. According to Duke University's postdoctoral services office, which is one university partnering with Camargo on this program, historically, PhD students and postdoctoral researchers were training for tenured faculty positions, but now only 20% of graduates with a PhD will go on to tenured academic appointments. With the decrease in academic appointments, more graduates with a PhD are looking for positions beyond academia and that includes positions in pharmaceutical research.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
